A survey commissioned by GS1 US found that 94 percent of U.S. adults were concerned about the frequency of food recalls in 2026, up from 93 percent in 2025. ^[1] Optiscan Imaging Ltd, a company listed on the Australian Securities Exchange under the ticker ASX:OIL, has initiated a new clinical study. ^[2] UBS initiated coverage of Getinge with a Neutral rating and a price target of 255 Swedish crowns, stating that the medical equipment maker's shares are priced as if quality issues are fully resolved. ^[3] 67 percent of survey respondents said they had avoided an entire food product category following a recall, up from 60 percent in 2025. ^[4] The survey indicated that 80 percent of respondents believed food recalls were effective in protecting public health and safety in 2026, down from 85 percent in 2025. ^[5] Optiscan Imaging Ltd has partnered with the Mayo Clinic to conduct this clinical evaluation. ^[6] The results of this study are intended to support the company's future submissions to the US Food and Drug Administration (FDA). ^[7] The study is based in the United States and focuses on imaging for head and neck cancer. ^[8] Remediation costs have amounted to almost 20% of the company's cumulative free cash flow since 2015, according to UBS. ^[9] UBS classified Getinge's portfolio into three buckets - Growth Accelerators, Steady Compounders, and Growth Detractors - with Growth Accelerators expected to rise from under 30% of sales in 2025 to almost 35% by 2030. ^[10] UBS forecasts Getinge to deliver a 5% revenue and 12% earnings-per-share compound annual growth rate for 2026-2030, driven by a portfolio mix shift toward higher-growth product categories. ^[11] 59 percent of respondents said they had discarded recalled food even when their state or region was not affected, compared with 57 percent in 2025. ^[12]